Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pacira Pharmaceuticals has reported new data supporting the use of Exparel through infiltration into the transversus abdominis plane (TAP) for the management of postsurgical pain.
Subscribe to our email newsletter
The open-label study enrolled 24 patients undergoing robotic prostatectomy to assess the safety and efficacy profile of bupivacaine liposome injectable suspension by means of TAP infiltration.
Prospective study observed that the patients on an average required less than one oxycodone/acetaminophen tablet each day from their discharge till tenth day vicit.
All the subjects in the trail demonstrated satisfied postsurgical pain control, with no treatment-related adverse events.
When compared with a study conducted in 2011 in patients who received a TAP infiltration of bupivacaine HCl retrospectively, patients who received Exparel in the identical fashion showed better pain scores along with minimal requirement for opoids.
A 300-patient survey conducted to review the existing state of postsurgical pain management demonstrated the presence of inadequately controlled postsurgical pain.